30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)

NCT01028391 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

317

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Sitagliptin 100 mg q.d.+ Pioglitazone 45 mg q.d.
DRUG: Pioglitazone 45 mg q.d. + Sitagliptin 100 mg placebo q.d.
DRUG: Metformin

Sponsor

Merck Sharp & Dohme LLC